The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
(2012) · Hepatogastroenterology · doi:10.5754/hge12458 · Cited by 1,977
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736
Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3397 · Cited by 1,180
The Two Faces of Interferon-γ in Cancer
Zaidi, M. R., & Merlino, G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0482 · Cited by 593
Myeloid-Derived Suppressor Cells
(2015) · Advances in Cancer Research · doi:10.1016/bs.acr.2015.04.002 · Cited by 482
Lee, S.-J., Jang, B.-C., Lee, S.-W., Yang, Y.-I., Suh, S.-I., Park, Y.-M., Oh, S., Shin, J.-G., Yao, S., Chen, L., et al. (2006) · FEBS Letters · doi:10.1016/j.febslet.2005.12.093 · Cited by 446
Morel, S., Lévy, F., Burlet-Schiltz, O., Brasseur, F., Probst-Kepper, M., Peitrequin, A.-L., Monsarrat, B., Van Velthoven, R., Cerottini, J.-C., Boon, T., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)80163-6 · Cited by 415
Indoleamine 2,3‐dioxygenase in T‐cell tolerance and tumoral immune escape
Katz, J. B., Muller, A. J., & Prendergast, G. C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00610.x · Cited by 398
Mandai, M., Hamanishi, J., Abiko, K., Matsumura, N., Baba, T., & Konishi, I. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0224 · Cited by 395
Heusinkveld, M., de Vos van Steenwijk, P. J., Goedemans, R., Ramwadhdoebe, T. H., Gorter, A., Welters, M. J. P., van Hall, T., & van der Burg, S. H. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100889 · Cited by 368
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
Park, J.-J., Omiya, R., Matsumura, Y., Sakoda, Y., Kuramasu, A., Augustine, M. M., Yao, S., Tsushima, F., Narazaki, H., Anand, S., et al. (2010) · Blood · doi:10.1182/blood-2010-01-265975 · Cited by 330
Immune escape as a fundamental trait of cancer: focus on IDO
Prendergast, G. C. (2008) · Oncogene · doi:10.1038/onc.2008.35 · Cited by 325
Selenko-Gebauer, N., Majdic, O., Szekeres, A., Höfler, G., Guthann, E., Korthäuer, U., Zlabinger, G., Steinberger, P., Pickl, W. F., Stockinger, H., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.7.3637 · Cited by 263
Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial
Windbichler, G. H., Hausmaninger, H., Stummvoll, W., Graf, A. H., Kainz, C., Lahodny, J., Denison, U., Müller-Holzner, E., & Marth, C. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1053 · Cited by 241
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
Schmidt, L. H., Kümmel, A., Görlich, D., Mohr, M., Bröckling, S., Mikesch, J. H., Grünewald, I., Marra, A., Schultheis, A. M., Wardelmann, E., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0136023 · Cited by 231
The role of tumor-associated macrophages in breast cancer progression
OBEID, E., NANDA, R., FU, Y.-X., & OLOPADE, O. I. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1938 · Cited by 204
The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo
Paterson, A. M., Brown, K. E., Keir, M. E., Vanguri, V. K., Riella, L. V., Chandraker, A., Sayegh, M. H., Blazar, B. R., Freeman, G. J., & Sharpe, A. H. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003496 · Cited by 202
Matsuura, H., Sakaue, M., Subbaramaiah, K., Kamitani, H., Eling, T. E., Dannenberg, A. J., Tanabe, T., Inoue, H., Arata, J., & Jetten, A. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.41.29138 · Cited by 187
Irmler, I. M., Gajda, M. R., & Bräuer, R. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.9.6228 · Cited by 129
Alberts, D. S., Marth, C., Alvarez, R. D., Johnson, G. A., Bidziński, M., Kardatzke, D. R., Bradford, W. Z., Loutit, J. S., Kirn, D. H., Clouser, M. C., et al. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.01.005 · Cited by 127
Meyskens, F. L., Kopecky, K. J., Taylor, C. W., Noyes, R. D., Tuthill, R. J., Hersh, E. M., Feun, L. G., Doroshow, J. H., Flaherty, L. E., & Sondak, V. K. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.22.1710 · Cited by 109
IFNγ Promotes Papilloma Development by Up-regulating Th17-Associated Inflammation
Xiao, M., Wang, C., Zhang, J., Li, Z., Zhao, X., & Qin, Z. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3479 · Cited by 108
Li, H., Yang, B. L., Huang, J., Lin, Y. S., Xiang, T., Wan, J., Li, H., Chouaïb, S., & Ren, G. (2015) · Oncotarget · doi:10.18632/oncotarget.4936 · Cited by 93
Self-citationSui, X., Ma, J., Han, W., Wang, X., Fang, Y., Li, D., Pan, H., & Zhang, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5107 · Cited by 82
Schalper, K. A. (2014) · OncoImmunology · doi:10.4161/onci.29288 · Cited by 73
Interferon γ: a master key in the immune system
Dijkmans, R., & Billiau, A. (1988) · Current Opinion in Immunology · doi:10.1016/0952-7915(88)90013-1 · Cited by 71
T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics
Barach, Y. S., Lee, J. S., & Zang, X. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.09.006 · Cited by 59
Regulatory T cells and potential inmmunotherapeutic targets in lung cancer
Zhang, D., Chen, Z., Wang, D. C., & Wang, X. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9566-0 · Cited by 43
Dynamic Interplay of Oncogenes and T Cells Induces PD-L1 in the Tumor Microenvironment
Rech, A. J., & Vonderheide, R. H. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0775 · Cited by 38
Rai, R. K., Vishvakarma, N. K., Mohapatra, T. M., et al. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182661afa · Cited by 19
Tumorassoziierte Makrophagen: Funktion und Differenzierung
Niedobitek, G., Barros, M. H. M., Dreyer, J. H., Hauck, F., & Al-Sheikhyaqoob, D. (2015) · Der Pathologe · doi:10.1007/s00292-015-0054-7 · Cited by 7
Cited by
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., Wu, X., Ma, J., Zhou, M., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0928-4 · Cited by 1,457
Roles of IFN-γ in tumor progression and regression: A review
Jorgovanovic, D., Song, M., Wang, L., & Zhang, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-00228-x · Cited by 1,234
Morrissey, S. M., Zhang, F., Ding, C., Montoya-Durango, D. E., Hu, X., Yang, C., Wang, Z., Yuan, F., Fox, M., Zhang, H.-G., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.09.002 · Cited by 605
Self-citationRoles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond
Ai, L., Xu, A., & Xu, J. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3266-5_3 · Cited by 526
Metadata
- Authors
- Zhang, X., Zeng, Y., Qu, Q., Zhu, J., Liu, Z., Ning, W., Zeng, H., Zhang, N., Du, W., Chen, C., & Huang, J.-A.
- Venue
- International Journal of Clinical Oncology
- Published
- 2017-07-26
- Volume
- 22
- Issue
- 6
- Pages
- 1026-1033
- ISSN
- 1341-9625 (ISSN-L)
- 1437-7772
- OpenAlex
- W2738879667
- Cited by
- 316
- References
- 38
- FWCI
- 8.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.